Why has BIEL been rising? |
 |
 |
| By Vinny Cassano |
| Wednesday, 10 March 2010 03:00 |
 Shares of BioElectronics enjoyed a nice jump in price this week based on the release of an interview with CEO Andy Whelan
on SmallCapVoice.com.In part one, the CEO touched on some very significant subjects regarding the company and while CEOs are always supposed to sound optimistic, Mr. Whelan made it clear that big things are on the horizon for BioElectronics; even going so far as to state that the company is on the verge of becoming a "very significant" one. Of immediate interest, Mr. Whelan was confident that BIEL would become a fully reporting company in a matter of weeks when the 2009 audit is complete, a significant stepping stone for the company to move to the OTCBB - although he didn't rule out the possibility of an eventual move to the big boards, but one thing at a time. Nothing new was released regarding the status of the 510k and re-classification issues with the FDA - it's a waiting game as the FDA becomes "educated" on the products - but the CEO was extremely confident that over the short to mid term, both the ActiPatch and Allay products would be approved for OTC in the United States. Maybe more significant to the stock's price action is the fact that many of the brokers that were not allowing investors to purchase shares of BIEL are now starting to allow the transactions. Mr. Whalen mentioned Schwab, but I know that there were others not allowing BIEL orders as well. The relaxing of the restrictions is sure to help the BIEL stock price - there were quite a few investors who were standing on the sidelines waiting to get (back) in or add to their positions. Whelan interview was highly encouraging and confirms what many investors in BIEL have believed for some time - that the company could be on the verge of making a big impact in the global pain & swelling market. By no means is BioElectronics in the clear - hurdles still remain, but those able to buy in at the three cent level will reap significant rewards down the road, in my opinion. Disclosure: long BIEL BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section Add this page to your favorite Social Bookmarking websites            |
about 10 hours ago
FDA panel votes against Xgeva; Nervous GlaxoSmithKline Pulls Cash Out of Eurozone: Below is a look at some of th... http://t.co/h6kQSAz6
about 1 day ago
Illumina’s Board Unanimously Rejects Roche’s Offer; Shire Announces FDA Approval of Vyvanse®: Below is a look at... http://t.co/L3FZivQV
about 1 day ago
Achillion ($ACHN) hammered after BofA rates to "Underperform" citing no M&A speculation. What we said last month: http://t.co/usWk95O6
about 2 days ago
Medgenics ($MDGN) up 10% on Monday! We first told you about the firm last Friday: http://t.co/aD50CMSH
about 2 days ago
Thinly traded BioLineRx shares move on hepatitis C deal: The shares of thinly traded BioLineRx (NASDAQ:BLRX) soa... http://t.co/ugbuZgNN
about 2 days ago
Orexigen® Announces Agreement From the FDA on a Special Protocol Assessment; Acorda Announces Launch of Generic ... http://t.co/vSt6VrLP
about 2 days ago
$CVM up 17% and technically looks like it may head higher.
about 2 days ago
$ANAC drops after GlaxoSmithKline (GSK) pauses enrollment for its clinical trials of its urinary tract infection drug. http://t.co/yUUSzkUr
Free Phone Trade Alerts
